Developer docs
API playgroundTry for free, no card

Search company profiles

Ronawk

Full company profile

uuid000244w

Namestring
Ronawk
Legal namestring
Ronawk, Inc.
Websiteurl
ronawk.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Ronawk, Inc. is a Delaware corporation founded in 2019 and headquartered in Olathe, Kansas, that develops a proprietary biomanufacturing platform branded as Bio-OS (Biological Operating System). The platform integrates modular hardware, standardized software, and proprietary wetware (living hydrogel components called Bio-Blocks) to recreate natural cellular microenvironments, enabling continuous and reproducible mammalian cell growth. Bio-OS is configured across four application areas — Manufacturing, Assembly, Diagnostic, and Engineering — and has been validated on over 100 cell types. Per the company's terms and conditions, products are sold and licensed solely for research and development purposes, restricting use to internal R&D.

Ronawk targets biopharmaceutical and biotech companies developing cell-based therapies, regenerative medicine products, and advanced biologics, as well as academic and commercial cell producers and research institutions. The company pursues an enterprise B2B go-to-market with direct sales engagement; prospective customers initiate a "Bio-OS program" through a structured contact process on the company website, with contact forms segmented by role (Business Professional, Cell Culture Scientist, Clinician, Commercial Cell Producer, R&D Regenerative Medicine, Reseller, Student, Other). Strategic partnerships announced in 2024-2025 include Cellipont Bioservices (cGMP MSC manufacturing), The Amnion Foundation (perinatal stem cells), and collaborations with the University of Florida and Nikon for translational and analytical applications.

Ronawk has raised approximately $8.4 million across disclosed funding rounds between 2020 and 2023, including seed and exempt securities offerings, with investors including Accelerate Venture Partners and undisclosed backers. Leadership comprises co-founders Dr. A.J. Mellott (CEO, tissue engineer) and Heather Decker (CTO, chemist/microscopist), alongside President & COO Tom Jantsch and CBDO Scott Leigh. The company operates with 11-50 employees and has reported no revenue. U.S. regulators are reportedly exploring Bio-OS as a new biomanufacturing standard, which, if formalized, could entrench the platform in regulated manufacturing workflows.

Short descriptiontext

Ronawk develops the Bio-OS platform, integrating modular hardware, software, and proprietary hydrogel wetware to enable scalable, reproducible mammalian cell manufacturing for biotech companies, research institutions, and commercial cell producers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOlathe, United States
HQ citystring
Olathe
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics manufacturing platform, cell culture technology, bioprocess hardware software, hydrogel cell growth, regenerative medicine tools
Industry4 codes
PRIMARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Bioprocess Technology
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Bio-OS Platform Products
TypeOne Time License
Description

Ronawk sells biological products (Bio-Blocks/hydrogels and potentially associated hardware/software) for research and development purposes. The Terms and Conditions indicate products are sold and licensed solely for research and development purposes, with payment terms of 30 days net. The company appears to operate on a direct B2B transactional model with no explicit recurring or subscription components described.

ronawk.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Bio-OS
Description

Ronawk's biological operating system platform that provides hardware, software, and wetware integration to make living systems programmable, scalable, and investable. It serves as biology's throughput architecture and programmability layer.

ronawk.com
Core offering1 text field

Ronawk develops and sells the Bio-OS™ platform, a Biological Operating System that integrates modular hardware, standardized software, and proprietary hydrogel wetware (Bio-Blocks®) to recreate natural cellular microenvironments, enabling continuous, scalable, and reproducible mammalian cell production for research and development use. The platform is offered in four configurations—Manufacturing, Assembly, Diagnostic, and Engineering—and is sold and licensed under 30-day net terms solely for R&D applications to biotech, pharmaceutical, research, and commercial cell producers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ~90% of drug candidates fail in development
+2 more records
Product overview1 text field

Ronawk offers a unified platform architecture centered on Bio-OS™. Bio-OS™ is the primary platform combining modular hardware, standardized software, and living wetware to make cell behavior consistent, predictable, and scalable. The Bio-Blocks® product, the company's first innovation of modular hydrogels, evolved into this Bio-OS platform. Bio-OS is configured for four application areas: Manufacturing (continuous cell production), Assembly (controlled assembly of multiple cell types into tissues), Diagnostic (extracting multiple data points from a single sample), and Engineering (control over cell phenotype).

Product and service2 records
1Bio-OS™ Platform
CategoryCell culture platform
Description

Ronawk's flagship Biological Operating System that combines modular hardware, standardized software, and living wetware (Bio-Blocks hydrogels) to recreate natural cellular microenvironments. Provides standardized, repeatable compute cores of biology that make mammalian cell behavior consistent, predictable, and scalable. Sold and licensed for research and development use only via direct enterprise sales engagement.

2Bio-Blocks®
CategoryCell culture consumable
Description

Modular hydrogel product that recreates real tissue environments, enabling mammalian cells to grow continuously while preserving function. Marketed as a registered product trademark and sold for research and development purposes as the wetware foundation that evolved into the Bio-OS platform.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Strategic collaboration to advance scalable expansion of high-quality mesenchymal stem cells (MSCs) for advanced biologics and regenerative medicine applications. Combines Cellipont's cGMP manufacturing and process development expertise with Ronawk's Bio-OS platform. Aims to close the manufacturing gap that has limited broad clinical adoption of MSC-based therapies, potentially accelerating therapeutic development across the biotech landscape.

2The Amnion Foundation, Inc
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Partnership to advance perinatal stem cell research. Collaborates with Ronawk to leverage Bio-OS platform capabilities for perinatal stem cell applications, expanding the platform's reach into specialized cell therapy research areas.

ronawk.com
3Micro-GRX and University of Florida
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Collaboration on translational research in advanced tissue engineering aboard the International Space Station, validating Bio-OS technology in microgravity environments for advanced tissue engineering applications.

ronawk.com
4Nikon
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2024-09-01
Description

Nikon published an application note on resolving subcellular detail in tissue mimetic culture using Ronawk's Bio-OS technology, demonstrating technical integration and validation of the platform.

ronawk.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Developer of organ-on-chip platforms for biological research. Comparable in aiming to replace traditional cell culture with physiologically relevant microfluidic systems.

TypeBroad incumbent
Description

Provides cell culture media, instruments, and bioproduction services. Broad incumbent with overlapping capabilities in cell manufacturing and process development.

3Corning Life Sciences
TypeBroad incumbent
Description

Major supplier of cell culture vessels, surfaces, and bioprocess systems. Incumbent in the very cell culture market Ronawk is positioning Bio-OS to disrupt.

TypeBroad incumbent
Description

Global bioprocess equipment leader (bioreactors, cell expansion platforms). Direct incumbent in biomanufacturing infrastructure that Ronawk aims to redefine for mammalian cells.

TypeBroad incumbent
Description

Leading CDMO for cell and gene therapies. Comparable in serving the same biotech customers Ronawk targets, with broader capabilities and much larger scale.

6Aspect Biosystems
TypeDirect peer
Description

Biotechnology company developing 3D bioprinted tissue therapeutics. Direct peer in modular tissue engineering and biofabrication platforms.

TypeDirect peer
Description

Pioneer in 3D bioprinting of human tissues, including hydrogels. Direct peer in tissue engineering using hydrogel-based biofabrication.

TypeDirect peer
Description

Leading bioprinting company offering hardware, bioinks, and workflows. Direct peer in tissue biofabrication and modular cell culture systems.

TypeDirect peer
Description

Provides cell manufacturing platforms, including the Prodigy system for automated cell processing. Direct peer in cell-based therapy bioprocessing.

TypeDirect peer
Description

CDMO specializing in cell-based therapy manufacturing. Ronawk's strategic partner for MSC expansion and a direct peer in the scalable cell manufacturing space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ronawk

Bioprocess Technologyronawk.com

Ronawk develops the Bio-OS platform, integrating modular hardware, software, and proprietary hydrogel wetware to enable scalable, reproducible mammalian cell manufacturing for biotech companies, research institutions, and commercial cell producers.

What Ronawk does

Ronawk, Inc. is a Delaware corporation founded in 2019 and headquartered in Olathe, Kansas, that develops a proprietary biomanufacturing platform branded as Bio-OS (Biological Operating System). The platform integrates modular hardware, standardized software, and proprietary wetware (living hydrogel components called Bio-Blocks) to recreate natural cellular microenvironments, enabling continuous and reproducible mammalian cell growth. Bio-OS is configured across four application areas — Manufacturing, Assembly, Diagnostic, and Engineering — and has been validated on over 100 cell types. Per the company's terms and conditions, products are sold and licensed solely for research and development purposes, restricting use to internal R&D.

Ronawk targets biopharmaceutical and biotech companies developing cell-based therapies, regenerative medicine products, and advanced biologics, as well as academic and commercial cell producers and research institutions. The company pursues an enterprise B2B go-to-market with direct sales engagement; prospective customers initiate a "Bio-OS program" through a structured contact process on the company website, with contact forms segmented by role (Business Professional, Cell Culture Scientist, Clinician, Commercial Cell Producer, R&D Regenerative Medicine, Reseller, Student, Other). Strategic partnerships announced in 2024-2025 include Cellipont Bioservices (cGMP MSC manufacturing), The Amnion Foundation (perinatal stem cells), and collaborations with the University of Florida and Nikon for translational and analytical applications.

Ronawk has raised approximately $8.4 million across disclosed funding rounds between 2020 and 2023, including seed and exempt securities offerings, with investors including Accelerate Venture Partners and undisclosed backers. Leadership comprises co-founders Dr. A.J. Mellott (CEO, tissue engineer) and Heather Decker (CTO, chemist/microscopist), alongside President & COO Tom Jantsch and CBDO Scott Leigh. The company operates with 11-50 employees and has reported no revenue. U.S. regulators are reportedly exploring Bio-OS as a new biomanufacturing standard, which, if formalized, could entrench the platform in regulated manufacturing workflows.

Ronawk firmographics

Firmographics
Name
Ronawk
Legal name
Ronawk, Inc.
Website
https://ronawk.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Ronawk develops the Bio-OS platform, integrating modular hardware, software, and proprietary hydrogel wetware to enable scalable, reproducible mammalian cell manufacturing for biotech companies, research institutions, and commercial cell producers.
Ownership category
akta.pro rank

Ronawk industry classification

Industry
Product category
Bioprocess Technology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Equipment and Supplies Manufacturing (3391)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Biologics manufacturing platform
  • Cell culture technology
  • Bioprocess hardware software
  • Hydrogel cell growth
  • Regenerative medicine tools

Where Ronawk is headquartered

Location

Headquarters

HQ city
Olathe
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ronawk business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Bio-OS Platform Products: Ronawk sells biological products (Bio-Blocks/hydrogels and potentially associated hardware/software) for research and development purposes. The Terms and Conditions indicate products are sold and licensed solely for research and development purposes, with payment terms of 30 days net. The company appears to operate on a direct B2B transactional model with no explicit recurring or subscription components described.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Ronawk product offering

Product offering

Core offering

Ronawk develops and sells the Bio-OS™ platform, a Biological Operating System that integrates modular hardware, standardized software, and proprietary hydrogel wetware (Bio-Blocks®) to recreate natural cellular microenvironments, enabling continuous, scalable, and reproducible mammalian cell production for research and development use. The platform is offered in four configurations—Manufacturing, Assembly, Diagnostic, and Engineering—and is sold and licensed under 30-day net terms solely for R&D applications to biotech, pharmaceutical, research, and commercial cell producers.

Product overview

Ronawk offers a unified platform architecture centered on Bio-OS™. Bio-OS™ is the primary platform combining modular hardware, standardized software, and living wetware to make cell behavior consistent, predictable, and scalable. The Bio-Blocks® product, the company's first innovation of modular hydrogels, evolved into this Bio-OS platform. Bio-OS is configured for four application areas: Manufacturing (continuous cell production), Assembly (controlled assembly of multiple cell types into tissues), Diagnostic (extracting multiple data points from a single sample), and Engineering (control over cell phenotype).

Differentiator

Problem solved

Functional benefit

Brands

  • Bio-OS: Ronawk's biological operating system platform that provides hardware, software, and wetware integration to make living systems programmable, scalable, and investable. It serves as biology's throughput architecture and programmability layer.

Products and services

  • Bio-OS™ Platform Ronawk's flagship Biological Operating System that combines modular hardware, standardized software, and living wetware (Bio-Blocks hydrogels) to recreate natural cellular microenvironments. Provides standardized, repeatable compute cores of biology that make mammalian cell behavior consistent, predictable, and scalable. Sold and licensed for research and development use only via direct enterprise sales engagement.
  • Bio-Blocks® Modular hydrogel product that recreates real tissue environments, enabling mammalian cells to grow continuously while preserving function. Marketed as a registered product trademark and sold for research and development purposes as the wetware foundation that evolved into the Bio-OS platform.

Quantifiable outcome

  • ~90% of drug candidates fail in development
  • +2 more outcomes

Companies that use Ronawk

Customer profile

Segments3 records

Ideal customer profiles3 records

Ronawk technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ronawk partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Cellipont BioservicescoreStrategic or Co-development Partner · 19 November 2025Strategic collaboration to advance scalable expansion of high-quality mesenchymal stem cells (MSCs) for advanced biologics and regenerative medicine applications. Combines Cellipont's cGMP manufacturing and process development expertise with Ronawk's Bio-OS platform. Aims to close the manufacturing gap that has limited broad clinical adoption of MSC-based therapies, potentially accelerating therapeutic development across the biotech landscape.
  • The Amnion Foundation, InccoreStrategic or Co-development Partner · 4 November 2025Partnership to advance perinatal stem cell research. Collaborates with Ronawk to leverage Bio-OS platform capabilities for perinatal stem cell applications, expanding the platform's reach into specialized cell therapy research areas.
  • Micro-GRX and University of FloridasupportingStrategic or Co-development Partner · 1 September 2024Collaboration on translational research in advanced tissue engineering aboard the International Space Station, validating Bio-OS technology in microgravity environments for advanced tissue engineering applications.
  • NikonsupportingTechnology or Integration · 1 September 2024Nikon published an application note on resolving subcellular detail in tissue mimetic culture using Ronawk's Bio-OS technology, demonstrating technical integration and validation of the platform.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Ronawk competitors and assessment

Company assessment

Emerging players

  • Emulate Inc. Developer of organ-on-chip platforms for biological research. Comparable in aiming to replace traditional cell culture with physiologically relevant microfluidic systems.

Broad incumbents

  • Thermo Fisher Scientific (Cell Therapy): Provides cell culture media, instruments, and bioproduction services. Broad incumbent with overlapping capabilities in cell manufacturing and process development.
  • Corning Life Sciences: Major supplier of cell culture vessels, surfaces, and bioprocess systems. Incumbent in the very cell culture market Ronawk is positioning Bio-OS to disrupt.
  • Sartorius AG: Global bioprocess equipment leader (bioreactors, cell expansion platforms). Direct incumbent in biomanufacturing infrastructure that Ronawk aims to redefine for mammalian cells.
  • Lonza Group: Leading CDMO for cell and gene therapies. Comparable in serving the same biotech customers Ronawk targets, with broader capabilities and much larger scale.

Direct peers

  • Aspect Biosystems: Biotechnology company developing 3D bioprinted tissue therapeutics. Direct peer in modular tissue engineering and biofabrication platforms.
  • Organovo: Pioneer in 3D bioprinting of human tissues, including hydrogels. Direct peer in tissue engineering using hydrogel-based biofabrication.
  • Cellink (BICO): Leading bioprinting company offering hardware, bioinks, and workflows. Direct peer in tissue biofabrication and modular cell culture systems.
  • Miltenyi Biotec: Provides cell manufacturing platforms, including the Prodigy system for automated cell processing. Direct peer in cell-based therapy bioprocessing.
  • Cellipont Bioservices: CDMO specializing in cell-based therapy manufacturing. Ronawk's strategic partner for MSC expansion and a direct peer in the scalable cell manufacturing space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Ronawk social profiles

Digital presence

Ronawk financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ronawk leadership team

Management profile

Number of profiles

Profiles4 records

Ronawk funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ronawk M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ronawk

What does Ronawk do?

Ronawk develops and sells the Bio-OS™ platform, a Biological Operating System that integrates modular hardware, standardized software, and proprietary hydrogel wetware (Bio-Blocks®) to recreate natural cellular microenvironments, enabling continuous, scalable, and reproducible mammalian cell production for research and development use. The platform is offered in four configurations—Manufacturing, Assembly, Diagnostic, and Engineering—and is sold and licensed under 30-day net terms solely for R&D applications to biotech, pharmaceutical, research, and commercial cell producers.

Is Ronawk a public or private company?

Ronawk is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ronawk founded?

Ronawk was founded in 2019. It employs 1 to 10 people.

Where is Ronawk based?

Ronawk is headquartered in Olathe, United States, in the North America region.

How does Ronawk make money?

One revenue line is on record: bio-OS Platform Products.

Who are Ronawk's main competitors?

Emulate Inc. is listed as an emerging player. Broad incumbents are Thermo Fisher Scientific (Cell Therapy), Corning Life Sciences, Sartorius AG and Lonza Group. Direct peers are Aspect Biosystems, Organovo, Cellink (BICO), Miltenyi Biotec and Cellipont Bioservices.

Does Ronawk have an API?

No public API is recorded for Ronawk.

What industry is Ronawk in?

Ronawk's product category is Bioprocess Technology. Its primary akta.pro industry code is HLAGAIAG, Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCellipont Bioservices and Ronawk Partner to Advance Scalable Expansion of High-Quality Mesenchymal Stem Cells and BiologicsCellipont Bioservices and Ronawk have announced a strategic collaboration to advance scalable expansion of high-quality mesenchymal stem cells for advanced biologics and regenerative medicine applications. The partnership combines Cellipont's cGMP manufacturing and process development expertise with Ronawk's Bio-OS™ platform, which recreates the natural cellular microenvironment, to address key industry challenges in scalability, consistency, and cost-effectiveness. This collaboration aims to close the manufacturing gap that has limited broad clinical adoption of MSC-based therapies, potentially accelerating therapeutic development across the biotech landscape.PR NewswireCellipont Bioservices and Ronawk Partner to Advance Scalable Expansion of High-Quality Mesenchymal Stem Cells and BiologicsCellipont Bioservices and Ronawk announced a strategic collaboration to accelerate scalable expansion of high-quality mesenchymal stem cells for regenerative medicine applications. The partnership combines Cellipont's cGMP manufacturing expertise with Ronawk's Bio-OS™ platform to address longstanding industry challenges in MSC scalability, consistency, and cost-effectiveness. This collaboration aims to advance next-generation cell-based therapies and accelerate therapeutic development across the biotech landscape.LinkedInHelex raises $3.5M for kidney gene therapies, expands platformRonawk, a biotech company based in Kansas City, announced that its chief scientific officer, Dr. Amy Manning-Bog, will leave the firm to launch her own venture focused on diagnostics and drug development. The transition is described by Ronawk's CEO as a positive evolution for both parties, marking the expansion of the local life sciences ecosystem. This event highlights the growing innovation culture within the region's biotech sector.KSHB 41 Kansas City NewsOverland Park biotech company's bio-block ready for space missionRonawk, an Overland Park biotech company, will send its bio-blocks to the International Space Station on a mission estimated for 2025-2026. The hydrogel scaffolds enable 3D cell growth, and collaborators like Micro-gRx and the University of Florida will use them for experiments.SecSEC FORM DRonawk, Inc. filed a Form D with the SEC reporting an exempt securities offering under Rule 506(b). The company raised a total of $6,484,707, comprising new cash investments and the conversion of existing convertible promissory notes. The filing indicates that five investors participated in this transaction.SecSEC FORM DRonawk, Inc. filed a Form D with the SEC for an exempt offering of securities under Rule 506(b), raising a total of $6,000,000 USD. The capital consists of $2,989,046.67 from the conversion of an existing convertible promissory note and $3,010,953.33 in new cash investments from one investor. The filing was submitted by President Thomas W. Jantsch on May 9, 2023.KcsourcelinkKC Area Startup Ronawk Has an Innovation That Could Change BiotechOverland Park, Kansas-based biotechnology startup Ronawk has developed a new technology called "Bio-Blocks" that enables efficient cell culturing for various research applications, including regenerative medicine and cancer. The company recently completed a $6.5 million Series A funding round to expand its operations, build a new lab, and support its subsidiary, STELL⍺, which provides research services to other biotech firms. Ronawk has engaged with over 120 companies and institutions in diverse projects and is focused on scaling its technology following ongoing product validation.SecSEC FORM DRonawk, Inc. filed a Form D with the SEC to report an exempt offering of securities under Rule 506(b). The company raised a total of $1,899,884, comprising $399,884.17 from the conversion of existing convertible promissory notes and $1,500,000 in new cash investments from 25 investors.